Joseph Sparano's guest appearances

Joseph Sparano

Einstein On...

Investigating Breast Cancer

Susan G. Komen Austin

Mina Bissell

Susan G. Komen

Tia Powell

Robert Schneider

Dan Kelly

Walter Willett

Michael Clarke

Paul Frenette

Nancy Brinker

Mark Robson

Greg Lee

David Goldman

Lawrence Shulman

Keith Ayoob

Larry Norton

OwlTail

Chemotherapy has been a gold standard for treatment of breast cancer and often over-treats women who may not need this aggressive treatment to treat their breast cancer.  Dr. Sparano serves as the study chair for the TAILORx clinical trial sponsored by National Cancer Institute, the first clinical trial integrating a mulitparameter gene expression assay in clinical decision making for adjuvant therapy with early stage ER-positive, HER2 negative breast cancer.  The results will eliminate the use of chemotherapy for thousands of women.

Eliminating Chemotherapy  - TailorX Study Results.  Dr. Joseph Sparano Series 2/Episode 8

It was among the biggest cancer news stories of the year: A new study – the largest breast cancer treatment trial ever conducted – showed no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. As the Washington Post described, that means: “most patients who have an intermediate risk of a cancer recurrence — a group that numbers 65,000 women a year in the United States — can avoid chemotherapy and its often debilitating side effects.” The TAILORx trial, as it is known, is helping change everyday procedures in the everyday lives of patients around the world. And the lead author is our guest today. Dr. Joseph Sparano is Professor at Albert Einstein College of Medicine. He is Vice-Chair, ECOG-ACRIN Cancer Research Group and has been a BCRF Investigator since 2012. I asked Dr. Sparano about the TAILORx study and how it feels to have been part of such landmark work. But I also asked Dr. Sparano about what’s next – about new work he’s doing around breast cancer recurrence – specifically relapses that occur many years after original diagnosis. 

It was among the biggest cancer news stories of the year: A new study – the largest breast cancer treatment trial ever conducted – showed no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. As the Washington Post described, that means: “most patients who have an intermediate risk of a cancer recurrence — a group that numbers 65,000 women a year in the United States — can avoid chemotherapy and its often debilitating side effects.” The TAILORx trial, as it is known, is helping change everyday procedures in the everyday lives of patients around the world. And the lead author is our guest today. Dr. Joseph Sparano is Professor at Albert Einstein College of Medicine. He is Vice-Chair, ECOG-ACRIN Cancer Research Group and has been a BCRF Investigator since 2012. I asked Dr. Sparano about the TAILORx study and how it feels to have been part of such landmark work. But I also asked Dr. Sparano about what’s next – about new work he’s doing around breast cancer recurrence – specifically relapses that occur many years after original diagnosis.

Avoiding chemotherapy, with Dr. Joseph Sparano

http://www.einstein.yu.edu - Physician-researcher Joseph Sparano, M.D., discusses the difference between personalized and precision medicine and explains how both are changing the treatment and outcomes for cancer patients. He also discusses research and clinical trials taking place at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Sparano is associate director for clinical research at Albert Einstein Cancer Center and associate chairman of medical oncology at Montefiore Einstein Center for Cancer Care. This edition of Einstein On, a research and medicine podcast, is hosted by Paul Moniz, managing director of communications and marketing.

<a href="http://www.einstein.yu.edu" rel="nofollow" target="_blank">http://www.einstein.yu.edu</a> - Physician-researcher Joseph Sparano, M.D., discusses the difference between personalized and precision medicine and explains how both are changing the treatment and outcomes for cancer patients. He also discusses research and clinical trials taking place at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Sparano is associate director for clinical research at Albert Einstein Cancer Center and associate chairman of medical oncology at Montefiore Einstein Center for Cancer Care. This edition of Einstein On, a research and medicine podcast, is hosted by Paul Moniz, managing director of communications and marketing.

Einstein On: Cancer, Dr. Joseph Sparano: Personalized Medicine